The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
K. Oda
No relevant relationships to disclose
K. Shoji
No relevant relationships to disclose
S. Nakagawa
No relevant relationships to disclose
T. Kashiyama
No relevant relationships to disclose
Y. Ikeda
No relevant relationships to disclose
Y. Miyamoto
No relevant relationships to disclose
M. Tanikawa
No relevant relationships to disclose
H. Kuramoto
No relevant relationships to disclose
M. Nishida
No relevant relationships to disclose
O. Hiraike-Wada
No relevant relationships to disclose
T. Yano
No relevant relationships to disclose
S. Kozuma
No relevant relationships to disclose
Y. Taketani
No relevant relationships to disclose